Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of worsening heart failure and mortality in patients with chronic heart failure across the full spectrum of left ventricular ejection fraction (LVEF).19 The gene discussed is SLC5A2; the disease is heart failure.